TOP 200 Companies filing patents this week Companies with the Most Patent Filings (2010+)
Web
Boehringer Ingelheim International Gmbh patents
Recent patent applications related to Boehringer Ingelheim International Gmbh. Boehringer Ingelheim International Gmbh is listed as an Agent/Assignee. Note: Boehringer Ingelheim International Gmbh may have other listings under different names/spellings. We're not affiliated with Boehringer Ingelheim International Gmbh, we're just tracking patents.
ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Boehringer Ingelheim International Gmbh-related inventors
Anti il-36r antibodies combination therapy
. . . . The present invention relates to anti-il-36r binding compounds, in particular new anti-il-36r antibodies and therapeutic and diagnostic methods and compositions for using the same.. . ... Boehringer Ingelheim International Gmbh
Treatment for diabetes in patients inappropriate for metformin therapy
The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.. . ... Boehringer Ingelheim International Gmbh
Cardio- and renoprotective antidiabetic therapy
The present invention relates to a certain dpp-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.. . ... Boehringer Ingelheim International Gmbh
. . . . . . . . A nebulizer is proposed which comprises a blocking device for blocking opening of the nebulizer in a tensioned state. The nebulizer comprises preferably an indicator device for indicating a tensioned state of the nebulizer. ... Boehringer Ingelheim International Gmbh
The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof.. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The invention relates to the treatment or prevention of renal impairment and/or complications using a sglt-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.. . ... Boehringer Ingelheim International Gmbh
Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
. . The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lung cancer, pancreatic cancer and skin cancer, for monitoring the effectiveness of cancer, such as lung cancer, pancreatic cancer and skin cancer treatment, and for drug development.. . ... Boehringer Ingelheim International Gmbh
Vegf-binding molecules, preferably vegf-binding immunoglobulin single variable domains like vhhs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with vegf-mediated effects on angiogenesis. Nucleic acids encoding vegf-binding molecules, host cells and methods for preparing same.. ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to certain sglt-2 inhibitors for treating and/or preventing metabolic disorders, such as type 1 or type 2 diabetes mellitus or pre-diabetes, in patients with renal impairment or chronic kidney disease (ckd).. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
. . The invention relates to a pharmaceutical composition according to the claim 1 comprising an sglt2 inhibitor and an insulin which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. ... Boehringer Ingelheim International Gmbh
. . Chimeric and humanized anti-cd37 antibodies and pharmaceutical compositions containing them are useful for the treatment of b cell malignancies and autoimmune and inflammatory diseases that involve b cells in their pathology.. . ... Boehringer Ingelheim International Gmbh
This invention relates to a novel synthetic method for the preparation of 6-substituted or 5,6-disubstituted derivatives of 2-amino-isonicotinic acid.. . ... Boehringer Ingelheim International Gmbh
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a dpp-4 inhibitor drug and/or a sglt-2 inhibitor drug, and metformin xr, processes for the preparation thereof, and their use to treat certain diseases.. . ... Boehringer Ingelheim International Gmbh
Binding molecules for the treatment of cancer
This invention relates to binding molecules that bind specifically to tnf-related apoptosis-inducing ligand receptor 2 (trailr2) and cadherin-17 (cdh17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.. . ... Boehringer Ingelheim International Gmbh
Process for the preparation of a xanthine-based compound
This invention relates to a method for preparation of a xanthine-based compound, as well as to intermediates useful in such preparation.. . ... Boehringer Ingelheim International Gmbh
Novel process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione
This invention relates to methods for the synthesis of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.. . ... Boehringer Ingelheim International Gmbh
Methods of treatment and pharmaceutical compositions using an sglt-2 inhibitor and a neuroleptic agent
The invention relates to methods for preventing, slowing the progression of, delaying or treating metabolic disorders induced in patients by the treatment with neuroleptic agents comprising administering to the patients an sglt2 inhibitor.. . ... Boehringer Ingelheim International Gmbh
Cell-controlled perfusion in continuous culture
Methods of protein production in continuous perfusion mammalian cell culture bioreactors are provided. Methods for continuous perfusion culture by allowing cells to self-regulate the rate of addition of perfusion medium to the bioreactor via a ph change are presented. ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. . ... Boehringer Ingelheim International Gmbh
Novel chiral dihydrobenzoazaphosphole ligands and synthesis thereof
This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. ... Boehringer Ingelheim International Gmbh
Novel chiral dihydrobenzooxaphosphole ligands and synthesis thereof
This invention relates to novel phosphorous ligands useful for organic transformations. Methods of making and using the ligands in organic synthesis are described. ... Boehringer Ingelheim International Gmbh
New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2-yl)-(1h-pyrazol-3-yl)-amines and derivatives as igf-1r/ir inhibitors
. . . . The present invention encompasses compounds of formula (i) wherein the groups a, r and q are defined in claim 1, their use as inhibitors of igf-1 r, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.. . ... Boehringer Ingelheim International Gmbh
Method and device for determination of water content
A method for determining water content of a preferably solid pharmaceutical preparation/sample, wherein at least two electrodes are brought into direct contact with the pharmaceutical preparation/sample in a measurement chamber such that the electrodes are electrically connected to one another via the pharmaceutical preparation/sample, and wherein a resistance of the pharmaceutical preparation/sample is determined by means of the electrodes and the water content and/or the sample quality of the pharmaceutical preparation/sample is determined with the ohmic resistance.. . ... Boehringer Ingelheim International Gmbh
Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide
The invention relates to spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide of general formula (i) which are inhibitors of phosphodiesterase 2, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.. ... Boehringer Ingelheim International Gmbh
Novel anti-baff antibodies
The present invention relates to anti-baff antibody molecules, including novel humanized anti-baff antibodies, therapeutic and diagnostic methods and compositions for using the same.. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to methods for treating or preventing chronic kidney disease and cardiovascular disease in patients with chronic kidney disease comprising administering empagliflozin to the patient.. . ... Boehringer Ingelheim International Gmbh
Cell engineering using rnas
The invention concerns the field of cell culture technology. It concerns rna having a specific sequence, expression vectors encoding said rna, production host cell lines comprising said rna, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said rnas, such as small non-coding rnas, preferably micrornas (mirnas). ... Boehringer Ingelheim International Gmbh
Methods of treating diseases
. . This invention generally relates to methods for the treatment of il-23 related diseases, in particular inflammatory diseases, such as crohn's disease, utilizing anti-il-23a antibodies.. . ... Boehringer Ingelheim International Gmbh
Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
The present invention relates to compounds of formula (i), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (tpsa) of at least 145, wherein r1, r2, r3, r4, x, and z− have one of the meanings as defined in the specification, to the use of compounds of formula (i) as a medicament, to pharmaceutical composition comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i).. . ... Boehringer Ingelheim International Gmbh
Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction
The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a sglt2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a sglt2 inhibitor is administered to the patient. ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.. . ... Boehringer Ingelheim International Gmbh
Polymorphs
The invention relates to polymorphous crystal modifications of a dpp-iv inhibitor, the preparation thereof and the use thereof for preparing a medicament.. . ... Boehringer Ingelheim International Gmbh
Acylated glucagon analogue
. . The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. ... Boehringer Ingelheim International Gmbh
Amylin analogues
. . . . . . . . . . . . The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.. ... Boehringer Ingelheim International Gmbh
Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
The present invention relates to pharmaceutical combinations cd33 antibodies and de-methylating agents for use in treating diseases like mds and cancer, especially aml.. . ... Boehringer Ingelheim International Gmbh
New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9
. . The present invention encompasses compounds of general formula (i) wherein the groups r1 to r9, x1 and x2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. ... Boehringer Ingelheim International Gmbh
Cx3cr1-binding polypeptides
. . . . The present invention relates to cx3cr1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.. ... Boehringer Ingelheim International Gmbh
New azabenzimidazole derivatives as agonists of the amp-activated protein kinase
The present invention relates to compounds of general formula i, wherein the group r1, x and y are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.. ... Boehringer Ingelheim International Gmbh
Immeadiate release oral tablet
A process for the preparation of an immediate release tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.. . ... Boehringer Ingelheim International Gmbh
Methods of treating diseases
. . . . This invention generally relates to methods for the treatment of respiratory diseases, such as asthma, utilizing anti-il-23a antibodies.. . ... Boehringer Ingelheim International Gmbh
Substituted benzimidazolium compounds useful in the treatment of respiratory diseases
The present invention relates to compounds of formula (i), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein r1, r2, r3, r4, x, and z have one of the meanings as defined in the specification, to the use of compounds of formula (i) as a medicament, to pharmaceutical composition comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i).. . ... Boehringer Ingelheim International Gmbh
New azabenzimidazole derivatives
The present invention relates to compounds of general formula (i), wherein r1, r2, r3, a1, a2, m and n are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the amp-activated protein kinase (ampk) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.. ... Boehringer Ingelheim International Gmbh
2-(pyrazin-2-ylcarbonylaminomethyl) benzimidazolium compounds as epithelial sodium channel inhibitors
The present invention relates to compounds of formula (i) or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (tpsa) of at least 145, wherein r1, r2, r3, r4, x, and z− have one of the meanings as defined in the specification, to the use of compounds of formula (i) as medicaments, to pharmaceutical compositions comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i). The compounds are enac inhibitors useful for the treatment of respiratory diseases and allergic diseases of the airways.. ... Boehringer Ingelheim International Gmbh
Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases
The present invention relates to compounds of formula (i), or the tautomers or pharmacologically acceptable acid addition salts thereof, wherein r1, r2, r3, r4, x, and z have one of the meanings as defined in the specification, to the use of compounds of formula (i) as a medicament, to pharmaceutical composition comprising at least one compound of formula (i), as well as to medicament combinations containing one or more compounds of formula (i).. . ... Boehringer Ingelheim International Gmbh
Oral disintegrating tablet
A process for the preparation of an oral disintegrating tablet comprising the antihypertensive telmisartan and the tablet obtained by the process.. . ... Boehringer Ingelheim International Gmbh
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.. . ... Boehringer Ingelheim International Gmbh
Novel propellant containing preparations for tiotropium
The present invention relates to a novel propellant-gas-containing medicament composition based on tiotropium 1, processes for the preparation thereof and the use of such medicament compositions in the treatment of respiratory complaints.. . ... Boehringer Ingelheim International Gmbh
Medical use of pharmaceutical combination or composition
The present invention relates to a certain dpp-4 inhibitor for use in combination with metformin in ckd patients.. . ... Boehringer Ingelheim International Gmbh
Vasoprotective and cardioprotective antidiabetic therapy
The present invention relates to certain dpp-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such dpp-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.. . ... Boehringer Ingelheim International Gmbh
Antibody molecules for cancer treatment
The present invention relates to novel anti-pd1 and anti-lag3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.. ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to certain sglt-2 inhibitors for treating, preventing, protecting against and/or delaying the progression of chronic kidney disease in patients, for example patients with prediabetes, type 1 or type 2 diabetes mellitus.. . ... Boehringer Ingelheim International Gmbh
Stable powder formulation containing an anticholingeric agent
. . A spray-dried powder formulation comprising particles that contain the following components i) to iii): i) anticholinergic agents, in particular at least one compound of formula 1, in which x− is a negatively charged anion, ii) at least one embedding material selected from the group consisting of mono- or disaccharides, oligosaccharides, polymers, sugar alcohols and cholesterol, and iii) an organic, physiologically acceptable, sterically demanding acid, selected from the group consisting of ascorbic acid, a monovalent, divalent or trivalent carboxylic acid, with the exception of amino carboxylic acids, preferably fumaric acid, oxalic acid, or diacetic acid, and a fruit acid or culinary acid, preferably citric acid, tartaric acid, malic acid, lactic acid, acetic acid, α-hydroxycaprylic acid or gluconic acid.. . ... Boehringer Ingelheim International Gmbh
Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists
. . The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (i), which are agonists of somatostatin receptor subtype 4 (sstr4), useful for preventing or treating medical disorders related to sstr4. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture of the compounds according to the invention.. ... Boehringer Ingelheim International Gmbh
Pharmaceutical formulation
The present invention relates to pharmaceutical formulations of highly active drugs with limited shelf-life in aqueous media, suitable to be administered by a caregiver person to a patient avoiding or minimizing the risk of exposure, contact or contamination of the caregiver person with the active product ingredient (api), preferably an egfr-tki such as afatinib dimaleate.. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The invention relates to a pharmaceutical composition according to the claim 1 comprising an sglt2 inhibitor and a glp-1 receptor agonist which is suitable in the treatment or prevention of diabetes mellitus, impaired glucose tolerance, hyperglycemia or other conditions. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.. ... Boehringer Ingelheim International Gmbh
Aldosterone synthase inhibitors
. . The present invention relates to compounds of the formulas (ia) and (ib) and pharmaceutically acceptable salts thereof, wherein a and r1-r6, are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.. ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The present invention relates to methods for preventing or treating acute or chronic heart failure and for reducing the risk of cardiovascular death, hospitalization for heart failure and other conditions in patients with preserved or reduced ejection fraction by administering empagliflozin to the patient.. . ... Boehringer Ingelheim International Gmbh
Bispecific binding molecules binding to vegf and ang2
Bispecifc binding molecules binding to both vegf and ang2, preferably in the form of immunoglobulin single variable domains like vhhs and domain antibodies, pharmaceutical compositions containing the same and their use in the treatment of diseases that are associated with vegf- and/or ang2-mediated effects on angiogenesis are disclosed. Further, nucleic acids encoding bispecific binding molecules, host cells and methods for preparing same are also described.. ... Boehringer Ingelheim International Gmbh
Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
The present invention encompasses compounds of formula (i) wherein the groups r1 to r7, a, v, w, x, y, n, r and q are defined in claim 1, their use as inhibitors of mdm2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.. . ... Boehringer Ingelheim International Gmbh
Novel process for the preparation of spiro[2.5]octane-5,7-dione and spiro[3.5]nonane-6,8-dione
This invention relates to methods for the synthesis of spiro[2.5]octane-5, 7-dione and spiro[3.5]nonane-6, 8-dione which are useful as intermediates in the manufacture of pharmaceutically active ingredients.. . ... Boehringer Ingelheim International Gmbh
Method and system for calculating a suitability indicator
Methods and systems for calculating a suitability indicator which corresponds to a suitability of a packaging system for packaging a substance, where a stability indicator which corresponds to a stability of the substance or of a component of the substance is determined as a function of at least one ambient condition, preferably the relative humidity and/or temperature of the environment of the substance, and the suitability indicator is calculated with at least one parameter relating to the ambient condition and with the stability indicator of the substance.. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical dosage form for immediate release of an indolinone derivative
The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.. . ... Boehringer Ingelheim International Gmbh
Nebulizer
. . A nebulizer for nebulizing a liquid from a container is proposed. The nebulizer comprises a liquid pump for withdrawing the liquid in doses from the container and pressurizing the respective doses for nebulization. ... Boehringer Ingelheim International Gmbh
Drug delivery device
A drug delivery device (100), in particular a nebulizer or inhaler, is proposed, wherein a collapsible container (16) is combined with a mechanism (30) to help the collapsing process and to prevent the collapsed container expanding again, hence preventing forming of vapor and gas bubbles within.. . ... Boehringer Ingelheim International Gmbh
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. . ... Boehringer Ingelheim International Gmbh
Cough syrup containing ambroxol hydrochloride
The present invention relates to cough syrups containing ambroxol hydrochloride, characterised in that they are substantially free from glycerol, and their use for mucolytic treatment in acute and chronic diseases of the bronchi and/or lungs.. . ... Boehringer Ingelheim International Gmbh
Biparatopic polypeptides antagonizing wnt signaling in tumor cells
. . . . The invention provides novel biparatopic lrp5/lrp6 cross-reactive binding polypeptides, and more specifically novel biparatopic lrp5/lrp6 cross-reactive immunoglobulin single variable domain constructs which can inhibit wnt signaling pathways. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as cancer.. ... Boehringer Ingelheim International Gmbh
Antidiabetic medications
Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.. . ... Boehringer Ingelheim International Gmbh
Combination therapy with volasertib
Disclosed is the use of volasertib or a salt or a hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) comprising administering a high dose of volasertib in combination with fludarabine, cytarabine and granulocyte colony-stimulating factor (gcsf) or in combination with fludarabine, cytarabine, gcsf and a daunorubicin citrate liposome injection.. . ... Boehringer Ingelheim International Gmbh
Biomarkers useful in the treatment of il-23a related diseases
This invention generally relates to biomarkers useful in the treatment of il-23 related diseases, in particular inflammatory diseases such as psoriasis. The invention also relates to methods of using the biomarkers disclosed herein, for example in therapies utilizing il-23 antagonists.. ... Boehringer Ingelheim International Gmbh
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i
The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. . ... Boehringer Ingelheim International Gmbh
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. . ... Boehringer Ingelheim International Gmbh
Treatment of myelodysplastic syndrome
The present invention relates to the use of volasertib or a pharmaceutically acceptable salt thereof or the hydrate thereof for treating myelodysplastic syndrome (mds).. . ... Boehringer Ingelheim International Gmbh
Combination therapy
The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a glp-1 receptor agonist and a dpp-4 inhibitor.. . ... Boehringer Ingelheim International Gmbh
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.. . ... Boehringer Ingelheim International Gmbh
Nebulizer and container
A nebulizer as well as a container with a fluid for such a nebulizer are proposed. The container comprises a control device which indicates initially an unused state of the container before first use. ... Boehringer Ingelheim International Gmbh
System with nebulizer and container
A system with a nebulizer as well as a container with a fluid and an indicator device for such a nebulizer are proposed. A check scheme is used for indicating the number of containers already used with the nebulizer or which still can be used with the nebulizer. ... Boehringer Ingelheim International Gmbh
Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a dpp-4 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.. . ... Boehringer Ingelheim International Gmbh
Ang2-binding molecules
. . Ang2-binding molecules, preferably ang2-binding immunoglobulin single variable domains like vhhs and domain antibodies, pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with ang2-mediated effects on angiogenesis. Nucleic acids encoding ang2-binding molecules, host cells and methods for preparing same.. ... Boehringer Ingelheim International Gmbh
Methods of treating diseases
The invention relates to the uses of an sglt-2 inhibitor, for example improving the health of a subject or treating metabolic myopathies.. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition and uses thereof
. . The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a dpp-4 inhibitor drug and/or a sglt-2 inhibitor drug, and metformin xr, processes for the preparation thereof, and their use to treat certain diseases.. . ... Boehringer Ingelheim International Gmbh
Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
The present invention relates inter alia to the use of selectively moisture-adjusted tabletting material in the preparation of mechanically stable oral tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing oral tablets.. . ... Boehringer Ingelheim International Gmbh
Cd33 binding agents
The present invention relates to immunotherapies that are based on myeloid cell depletion. In particular, the present invention relates to cd33 binding agents for use in such therapies, e.g. ... Boehringer Ingelheim International Gmbh
Anticancer combination therapy
The invention describes anti-cancer therapies comprising using a 3g-egfr inhibitor and an anti-igf antibody, each as described herein.. . ... Boehringer Ingelheim International Gmbh
Uses of dpp iv inhibitors
The specification describes the use of selected dpp iv inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned dpp iv inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. ... Boehringer Ingelheim International Gmbh
Methods of treating inflammatory diseases
. . This invention generally relates to methods for the treatment of il-23 related diseases, in particular inflammatory diseases, such as crohn's disease, utilizing anti-il-23a antibodies.. . ... Boehringer Ingelheim International Gmbh
Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
The present invention relates to a drying process of bibw 2992 or the salts thereof, preferably the dimaleate salt, as well as of solid pharmaceutical formulations comprising bibw2992 or a salt thereof, and to pharmaceutical compositions comprising bibw 2992 or a salt thereof as the active product ingredient, characterized by a water activity of the formulation of not more than 0.20 or a water content (karl-fischer) of not more than 4.2%.. . ... Boehringer Ingelheim International Gmbh
Nebulizer
. . . . A nebulizer is proposed which receives a container with a fluid and an indicator device. The indicator device stops further use of the container in a locked state when a predetermined number of uses has been reached or exceeded. ... Boehringer Ingelheim International Gmbh
Nebulizer and container
A nebulizer and a container with a fluid for such a nebulizer are proposed. The container comprises an indicator device fixedly mounted on the bottom of the container. ... Boehringer Ingelheim International Gmbh
Nebulizer
A nebulizer comprises a replaceable container with fluid to be nebulized. The container comprises an inseparable indicator device. ... Boehringer Ingelheim International Gmbh
Fast dissolving granulate
The invention relates to a fast dissolving granulate obtainable by spray-dying of a composition comprising a dry methanolic or ethanolic extract of valerian root, a dry methanolic extract of hop strobiles, optionally a carrier, one or more artificial sweeteners, one or more flavoring agents, optionally an acidifier and water for the treatment of sleep disorders, wherein the said granulate is to be administered upon dissolution in water or an aqueous beverage shortly before bedtime.. . ... Boehringer Ingelheim International Gmbh
Cardio- and renoprotective antidiabetic therapy
The present invention relates to a certain dpp-4 inhibitor for use in cardio- and/or renoprotective therapy, including in patients at high vascular risk.. . ... Boehringer Ingelheim International Gmbh
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
The present invention relates to methods for treating and/or preventing podocytes related disorders and/or nephrotic syndrome comprising the administration of an effective amount of a certain dpp-4 inhibitor, as well as to the use of a certain dpp-4 inhibitor for treating and/or preventing a metabolic disease in a patient with or at risk of podocytes related disorders and/or nephrotic syndrome.. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical dosage form for immediate release of an indolinone derivative
The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.. . ... Boehringer Ingelheim International Gmbh
Anti-cd40 antibodies
The present invention relates to new humanized antagonistic anti-cd40 antibodies and therapeutic and diagnostic methods and compositions for using the same.. . ... Boehringer Ingelheim International Gmbh
Use of anti-cd40 antibodies for treatment of lupus nephritis
The present invention relates to new humanized antagonistic anti-cd40 antibodies and therapeutic and diagnostic methods and compositions for using the same for treating and/or preventing lupus nephritis.. . ... Boehringer Ingelheim International Gmbh
Container, indicator device, and nebulizer
. . A nebulizer as well as a container and an indicator device for such a nebulizer are proposed. The indicator device is fixedly mounted from the bottom of the container and comprises a piercing element for opening an aeration of the container. ... Boehringer Ingelheim International Gmbh
Combination therapy for treating hcv infection
The present invention relates to therapeutic combinations comprising faldaprevir, sofosbuvir, ledipasvir and, optionally, ribavirin, and methods of using such therapeutic combinations for treating hcv infection in a patient.. . ... Boehringer Ingelheim International Gmbh
Methods, apparatuses, and systems for continuously inactivating a virus during manufacture of a biological product
. . Methods for continuously inactivating virus during manufacture of a biological product are provided. The methods include steps of (1) combining (a) a composition including a biological product, and (b) a composition including a virus-inactivation reagent, to obtain (c) a treatment composition having a predetermined property for inactivation of a virus, (2) confirming that the treatment composition exhibits the predetermined property, (3) transferring the treatment composition to a treatment vessel that includes an inlet, an outlet, and a static mixer, the transferring occurring at the inlet, (4) incubating the treatment composition in the treatment vessel at a predetermined temperature while the treatment composition flows at a predetermined rate and contacts the static mixer, and (5) collecting the treatment composition from the treatment vessel at the outlet, wherein steps (1) to (5) are carried out continuously. ... Boehringer Ingelheim International Gmbh
Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
The invention relates to an improved process for preparing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines.. . ... Boehringer Ingelheim International Gmbh
Polymorphs
. . The invention relates to polymorphous crystal modifications of a dpp-iv inhibitor, the preparation thereof and the use thereof for preparing a medicament.. . ... Boehringer Ingelheim International Gmbh
Pharmaceutical composition, methods for treating and uses thereof
The invention relates to the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia using a sglt-2 inhibitor. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.. ... Boehringer Ingelheim International Gmbh
Treatment for diabetes in patients inappropriate for metformin therapy
The present invention relates to the finding that certain dpp-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.. . ... Boehringer Ingelheim International Gmbh
Heteroaryl syk inhibitors
. . The invention relates to new substituted heteroaryls of formula 1 wherein a is selected from the group consisting of n and ch d is selected from the group consisting of ch, n, nh, e is c, t is selected from the group consisting of c and n, g is selected from the group consisting of c and n, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein r1, m and r3 are defined according to claim 1, and to the above compounds for the treatment of a disease selected from the group consisting of asthma, copd, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.. . ... Boehringer Ingelheim International Gmbh
Multi-specific binding proteins
This invention generally relates to multi-specific binding proteins. The invention also relates to methods of making such proteins and to methods of using such proteins. ... Boehringer Ingelheim International Gmbh
ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
###
This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Boehringer Ingelheim International Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Boehringer Ingelheim International Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com
###